Table 1: Basic Characteristics of the Patients on Admission.
| Characteristic | All Patients (n=62) | TR Only (n=25) | MR Only (n=9) | Both (n=28) | Number of Reported Data (TR/MR/Both) | Number of Missing Data (TR/MR/Both) |
|---|---|---|---|---|---|---|
| Sex, n (%) | ||||||
| Male | 12 (19.35) | 4 (16.00) | 3 (33.33) | 5 (17.86) | 62 (25/9/2028) | 0 (0/0/0) |
| Female | 50 (80.65) | 21 (84.00) | 6 (66.67) | 23 (82.14) | ||
| Age (years) | 45.77 ± 13.41 | 44.00 ± 12.56 | 47.11 ± 14.23 | 47.11 ± 14.23 | 62 (25/9/2028) | 0 (0/0/0) |
| Regions, n (%) | ||||||
| Asia | 29 (46.77) | 12 (48.00) | 4 (44.44) | 13 (46.43) | ||
| America | 21 (33.87) | 8 (32.00) | 4 (44.44) | 9 (32.14) | 62 (25/9/2028) | 0 (0/0/0) |
| Europe | 8 (12.90) | 3 (12.00) | 1 (11.11) | 4 (14.29) | ||
| Oceania | 3 (4.84) | 2 (8.00) | 0 (0.00) | 1 (3.57) | ||
| Africa | 1 (1.61) | 0 (0.00) | 0 (0.00) | 1 (3.57) | ||
| Follow-up (days) | 90.00 (38.50; 300.00) | 180.00 (45.50; 450.00) | 60.00 (31.00; 330.00) | 75.00 (28.00; 180.00) | 50 (21/5/2024) | 12 (4/4/4) |
| Follow-up (months) | 3.00 (1.38; 10.00) | 6.00 (1.63; 15.00) | 2.00 (1.04; 11.00) | 2.50 (1.00; 6.00) | 50 (21/5/2024) | 12 (4/4/4) |
| Underlying hyperthyroid disease, n (%) | ||||||
| Graves’ disease | 47 (75.81) | 17 (68.00) | 7 (77.78) | 23 (82.14) | 62 (25/9/2028) | 0 (0/0/0) |
| Other than Graves’ disease | 15 (24.19) | 8 (32.00) | 2 (22.22) | 5 (17.86) | ||
| Hyperthyroid status on admission, n (%) | ||||||
| Thyrotoxicosis | 36 (58.06) | 20 (80.00) | 4 (44.44) | 12 (42.86) | 62 (25/9/2028) | 0 (0/0/0) |
| Impending thyroid storm | 3 (4.84) | 1 (4.00) | 0 (0.00) | 2 (7.14) | ||
| Thyroid storm | 23 (37.10) | 4 (16.00) | 5 (55.56) | 14 (50.00) | ||
| BWPS on admission | 50.00 (40.00; 65.00) | 35.00 (15.00; 65.00) | 52.50 (38.75; 71.25) | 55.00 (42.50; 65.00) | 31 (8/6/17) | 31 (17/3/2011) |
| Thyroid laboratory parameters on admission | ||||||
| TSH (mIU/l) | 0.010 (0.005; 0.012) | 0.010 (0.006; 0.038) | 0.008 (0.005;0.017) | 0.010 (0.005; 0.010) | 53 (21/6/2026) | 9 (4/3/2) |
| fT4 (ng/dl) | 5.23 (3.64; 7.70) | 5.30 (3.71; 6.60) | 6.63 (3.34; 7.77) | 4.61 (3.43; 7.93) | 52 (19/5/2028) | 10 (6/4/0) |
| fT3 (pg/ml) | 20.00 (11.83; 28.31) | 19.26 (14.30;1,039.69) | 26.60 (20.64; N/A) | 15.69 (8.66; 25.00) | 31 (10/2/2019) | 31 (15/7/9) |
| TRAb, n (%) | ||||||
| Positive | 24 (92.31) | 8 (100.00) | 3 (100.00) | 13 (86.67) | 26 (8/3/15) | 36 (17/6/2013) |
| Negative | 2 (7.69) | 0 (0.00) | 0 (0.00) | 2 (13.33) | ||
| TSAb or TSI, n (%) | ||||||
| Positive | 11 (91.67) | 3 (100.00) | 2 (100.00) | 6 (85.71) | 12 (3/2/7) | 50 (22/7/2021) |
| Negative | 1 (8.33) | 0 (0.00) | 0 (0.00) | 1 (14.29) | ||
| TgAb, n (%) | ||||||
| Positive | 6 (42.86) | 3 (42.86) | 0 (0.00) | 3 (50.00) | 14 (7/1/6) | 48 (18/8/2022) |
| Negative | 8 (57.14) | 4 (57.14) | 1 (100.00) | 3 (50.00) | ||
| TPOAb or anti-microsomal antibodies, n (%) | ||||||
| Positive | 21 (80.77) | 7 (70.00) | 2 (66.67) | 12 (92.31) | 26 (10/3/2013) | 36 (15/6/2015) |
| Negative | 5 (19.23) | 3 (30.00) | 1 (33.33) | 1 (7.69) | ||
| Clinical evidence of HF on admission, n (%) | ||||||
| Yes | 56 (90.32) | 22 (88.00) | 8 (88.89) | 26 (92.86) | 62 (25/9/2028) | 0 (0/0/0) |
| None | 6 (9.68) | 3 (12.00) | 1 (11.11) | 2 (7.14) | ||
| Clinical condition after the first discharge to outpatient, n (%) | ||||||
| Improved/ recovered | 46 (74.19) | 17 (68.00) | 7 (77.78) | 22 (78.57) | ||
| Improved followed by readmission | 3 (4.84) | 2 (8.00) | 0 (0.00) | 1 (3.57) | 62 (25/9/2028) | 0 (0/0/0) |
| Improved with any persistent conditions | 7 (11.30) | 3 (12.00) | 1 (11.11) | 3 (10.71) | ||
| Died | 4 (6.45) | 2 (8.00) | 1 (11.11) | 1 (3.57) | ||
| Unclear | 2 (3.23) | 1 (4.00) | 0 (0.00) | 1 (3.57) | ||
| Final follow-up of thyroid status, n (%) | ||||||
| Euthyroid, on medication | 20 (32.26) | 10 (40.00) | 2 (22.22) | 8 (28.57) | ||
| Euthyroid, off medication | 6 (9.68) | 2 (8.00) | 0 (0.00) | 4 (14.29) | ||
| Euthyroid, unclear medication status | 14 (22.58) | 5 (20.00) | 3 (33.33) | 6 (21.43) | 62 (25/9/2028) | 0 (0/0/0) |
| Uncontrolled, poor compliance | 10 (27.78) | 0 (0.00) | 0 (0.00) | 1 (3.57) | ||
| Hypothyroid | 3 (4.84) | 0 (0.00) | 1 (11.11) | 2 (7.14) | ||
| LTFU | 1 (1.61) | 0 (0.00) | 0 (0.00) | 1 (3.57) | ||
| Unclear | 17 (27.42) | 8 (32.00) | 3 (33.33) | 6 (21.43) | ||
Data are presented in n (%), or mean ± SD, or median (interquartile range). BWPS = Burch-Wartofsky Point Scale; fT3 = free triiodothyronine; fT4 = free thyroxine; HF = heart failure; LTFU = lost to follow-up; MR = mitral regurgitation; TgAb = thyroglobulin antibody; TPOAb = thyroid peroxidase antibody; TR = tricuspid regurgitation; TRAb = TSH-receptor antibody; TSAb = thyroid-stimulating antibody; TSH = thyroid-stimulating hormone; TSI = thyroid-stimulating immunoglobulin.